RxDoctor Payments Data

Jamie Sheth, MD

Pulmonary Disease · Ann Arbor, MINPI 1982923439

Payments from drug & device makers

What this record shows

This record is dominated by education: $15 of the $15 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, AstraZeneca. That places this record below the midpoint for pulmonary disease clinicians in MI, where the typical reported total is $1,164.

$15in general payments, 2019–2025

Across 1 payment — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$15
$734,781in research payments, 2019–2025

Across 107 payments — averaging $6867.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$410K
  • GSK$166K
  • E.r. Squibb & Sons, L.L.C.$145K
  • Boehringer Ingelheim International GmbH$14K

What the payments were for

  • Education$15100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$15

How this compares

$15 in reported general payments places this provider in the 5th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$74,146
Medicare patients
869
Services billed
2,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate129$1,711,436
Trelegy ElliptaFluticasone/Umeclidin/Vilanter160$134,985
Dupixent PenDupilumab24$86,809
Pirfenidone24$40,820
Breo ElliptaFluticasone/Vilanterol60$38,178
Advair HfaFluticasone Propion/Salmeterol74$30,369
SymbicortBudesonide/Formoterol Fumarate90$27,263
Spiriva RespimatTiotropium Bromide34$26,474
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate91$25,161
Incruse ElliptaUmeclidinium Bromide55$24,020
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$14,522
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$13,874
DuleraMometasone/Formoterol29$12,752
Tiotropium Bromide23$12,056
Spiriva HandihalerTiotropium Bromide14$10,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort, Breztri Aerosphere$15$37,405105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →